Prophylactic Probiotics in Premature Infants (C3P)
|First Received Date ICMJE||July 31, 2008|
|Last Updated Date||June 21, 2011|
|Start Date ICMJE||August 2008|
|Primary Completion Date||June 2011 (final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Number of deaths and episodes of nosocomial sepsis among probiotic exposed and non-exposed preterm infants [ Time Frame: From birth to discharge from the NICU or death. Average time 2 months. ] [ Designated as safety issue: Yes ]
Premature infants randomized within the first 48 hours of birth will be followed prospectively to determine number of deaths and episodes of nosocomial sepsis between placebo and control groups.
|Original Primary Outcome Measures ICMJE
||Prevention of death or nosocomial sepsis in preterm infants [ Time Frame: At discharge from the NICU ] [ Designated as safety issue: Yes ]|
|Change History||Complete list of historical versions of study NCT00727363 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Number of episodes of necrotizing enterocolitis experienced by each premature infant randomized to probiotic exposure or to placebo [ Time Frame: From birth to discharge from the NICU or death. Average time: 2 months ] [ Designated as safety issue: No ]
Premature infants randomized to placebo or treatment within the first 48 hours of birth will be followed prospectively to determine number of necrotizing enterocolitis episodes experienced using a modification of Bells criteria for Stage 2.
|Original Secondary Outcome Measures ICMJE
||necrotizing enterocolitis [ Time Frame: At discharge from the NICU ] [ Designated as safety issue: No ]|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Prophylactic Probiotics in Premature Infants|
|Official Title ICMJE||Prophylactic Probiotics for the Prevention of Sepsis and NEC in Premature Infants in Colombia. A Randomized Double-Blind, Multicenter Trial|
This study tries to determine whether the oral administration of a specific probiotic (good bacteria) in premature infants hospitalized in a neonatal intensive care unit may prevent infections and the development of a severe inflammatory disease of the bowel called necrotizing enterocolitis. The investigators propose that premature infants not given probiotics will colonize their gut with bad bacterias and develop infection.
Neonatal infections currently cause about 1.6 million deaths annually in developing countries. Preterm infants are especially vulnerable to infections because of their immature immune responses and their exposure to the hospital milieu which promotes gastrointestinal colonization with Gram-negative pathogens. Multiple studies have shown that the colonization of the bowel with probiotics (nonpathogenic anaerobic bacteria) competitively inhibit the attachment of Gram-negative pathogens decreasing their likelihood for bacterial translocation and the development of life threatening infections.This potentially high-impact, low-cost intervention may significantly improve the survival and morbidity of preterm infants around the world.
We seek to determine whether prophylactic administration of Lactobacillus reuteri decreases the incidence of death and nosocomial sepsis among susceptible preterm infants in a neonatal care setting in Colombia.
RESEARCH DESIGN AND METHODS
Multi-center, double-blind, randomized, placebo-controlled trial Primary outcome: Death or nosocomial sepsis Secondary outcomes: NEC, prevalence of Gram-negative pathogens, duration of hospitalization, and frequency of outpatient treatment and re-admission for infectious causes at 6 months post-discharge. Post-hoc analysis will evaluate differences in RCT outcomes in two key subgroups: breast-fed and formula-fed infants and vaginal delivery versus cesarean section, in both probiotic exposed and unexposed infants. In addition, we will look at death and nosocomial sepsis as separate outcomes to ensure there is no differential effect of treatment in either outcome. Location: 11 NICUs in Colombia.
Randomization and Stratification:
Stratification according to participating institutions will be done in order to control for center-related differences. Stratification by birth weight will be performed in 2 groups: < 1500 grams and 1501 to 2000 grams. When eligibility criteria are met, infants will be randomly assigned to treatment with probiotics or placebo by using a computerized stratified balanced block randomization design. Assignment to treatment will be accomplished using sealed, sequentially numbered, opaque envelopes, color-coded for strata, available in each NICU pharmacy.
Study patients will be randomized at birth to either placebo or probiotic administration (treatment group). The hospital pharmacy will be in charge of random allocation. Vials of probiotic and placebo will only be identified by the pharmacist and according to randomization will be sent to the NICU for administration to the patient. For those randomized to the treatment arm, L reuteri DSM 17938 will be administered at a dose of 10 to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital. This oil suspension is stable for 21 months at 2o C to 8o C (as documented by the manufacturer, BioGaia AB, Stockholm, Sweden). For those randomized to the placebo arm, patients will receive an equal number of drops from an identical vial containing only the oil base, but without the probiotic. The above preparations will be administered even if the patient has not begun a feeding protocol if there are no contraindications for feeding. Patients will be stratified according to their exposure to breast milk or premature infant formula alone or a combination of both. Infants of mothers with insufficient production of breast milk will be offered premature formula.
Feeding and nutrition protocols will be standardized among participating institutions to minimize the confounding effects of diverse practices. A standard feeding protocol may be started at 24-48 hours of life at a volume of 10 ml/kg/day if the patient is hemodynamically stable, defined as having a stable blood pressure. The two milliliters of breast milk or premature infant formula will be subtracted from this total daily volume. Feedings will be advanced slowly at a volume between 10 and 20 ml/kg/day depending on tolerance.84 Umbilical lines may be removed once feeds are increased above 20 ml/kg/day. Parenteral nutrition will be started on the second day of life according to a standardized protocol. MCT oil (2 kcal/30ml) will be used as a dietary supplement to increases the energy content of breast milk or formula when needed. Human milk fortifiers may be started once full enteral feeds have been tolerated. Feedings will be discontinued and an abdominal radiograph taken if there are any signs of feeding intolerance (recurrent emesis, gastric aspirate > 50% of previous feeding with abdominal distension or the presence of macroscopic blood in stools). In situations where feeds have been temporarily discontinued, patients may re-enter the study at the initiation of feeds. Patients who develop NEC may continue in the study if they are able to resume feeds after treatment. Inotropic support, if being weaned, is not a contraindication to begin or continue the protocol. Administration of probiotic will end at discharge, but the infant's status will continue to be monitored until 6 months post-discharge. Patient's participation in the study will end at 6 months post-discharge, or upon the death of the patient.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 3|
|Study Design ICMJE||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
|Study Arm (s)||
|Publications *||Rojas MA, Lozano JM, Rojas MX, Rodriguez VA, Rondon MA, Bastidas JA, Perez LA, Rojas C, Ovalle O, Garcia-Harker JE, Tamayo ME, Ruiz GC, Ballesteros A, Archila MM, Arevalo M. Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics. 2012 Nov;130(5):e1113-20. doi: 10.1542/peds.2011-3584. Epub 2012 Oct 15.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Terminated|
|Estimated Completion Date||August 2011|
|Primary Completion Date||June 2011 (final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||up to 48 Hours|
|Accepts Healthy Volunteers||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Colombia|
|Removed Location Countries|
|NCT Number ICMJE||NCT00727363|
|Other Study ID Numbers ICMJE||CNRNProbiotics|
|Has Data Monitoring Committee||Yes|
|Responsible Party||Mario Augusto Rojas MD, MPH, Vanderbilt University|
|Study Sponsor ICMJE||Colombian Neonatal Research Network|
|Information Provided By||Colombian Neonatal Research Network|
|Verification Date||June 2011|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP